Key result
SMTNL1 deletion increases MYPT1 expression ~35-fold, reducing vascular smooth muscle force in neonates and pregnancy.
SMTNL1 is a key regulator of MYPT1 expression, mediating smooth and striated muscle adaptations during sexual development and pregnancy.
SMTNL1 may mediate pregnancy vascular and uterine adaptations; leaves open clinical relevance pending in vivo validation.
Pregnancy coordinately alters the contractile properties of both vascular and uterine smooth muscles reducing systemic blood pressure and maintaining uterine relaxation. The precise molecular mechanisms underlying these pregnancy-induced adaptations have yet to be fully defined but are likely to involve changes in the expression of proteins regulating myosin phosphorylation. Here we show that smoothelin like protein 1 (SMTNL1) is a key factor governing sexual development and pregnancy induced adaptations in smooth and striated muscle. A primary target gene of SMTNL1 in these muscles is myosin phosphatase-targeting subunit 1 (MYPT1). Deletion of SMTNL1 increases expression of MYPT1 30-40-fold in neonates and during development expression of both SMTNL1 and MYPT1 increases over 20-fold. Pregnancy also regulates SMTNL1 and MYPT1 expression, and deletion SMTNL1 greatly exaggerates expression of MYPT1 in vascular smooth muscle, producing a profound reduction in force development in response to phenylephrine as well as sensitizing the muscle to acetylcholine. We also show that MYPT1 is expressed in Type2a muscle fibers in mice and humans and its expression is regulated during pregnancy, suggesting unrecognized roles in mediating skeletal muscle plasticity in both species. Our findings define a new conserved pathway in which sexual development and pregnancy mediate smooth and striated muscle adaptations through SMTNL1 and MYPT1.
No takes yet. Share an insight, caveat, or question.
Lontay et al. (2010) studied Pregnancy-induced adaptations in smooth and striated muscle. Deletion of SMTNL1 vs. Wild-type (implied) was evaluated on Expression of MYPT1 and contractile properties. Deletion of SMTNL1 increases MYPT1 expression 30-40-fold in neonates and exaggerates its expression during pregnancy, reducing force development in vascular smooth muscle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: